Kerri Fitzgerald

DocwireNews

Here are the top stories covered by DocWire Newsthis week in the Hematology &amp; Oncology section. This week, the Institute for Clinical and Economic Review (ICER) indicated that two cancer drugs had some of the biggest price increases last year, a study showed that triplet therapy for pancreatic cancer improves survival, and more.<a href="https://www.docwirenews.com/hematology-oncology/two-cancer-drugs-included-on-icers-list-of-drugs-with-biggest-price-increases/">Rituxan&reg; (rituximab) and&nbsp;Neulasta&reg; (pegfilgrastim)&nbsp;</a>were included on ICER&rsquo;s list of drugs with the biggest price increases from 2017 to 2018. The first annual report on Unsupported Price Increases of prescription drugs in the United States noted that the price hikes were more than twice the rate of medical inflation and were not supported by any new clinical evidence.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/triplet-pancreatic-cancer-regimen-demonstrates-encouraging-survival/">The addition of cisplatin</a> to Abraxane&reg; (nab-paclitaxel) and Gemzar&reg; (gemcitabine) improved survival in patients with&nbsp;pancreatic cancer, according to a study published in&nbsp;JAMA Oncology.According to a study&nbsp;published&nbsp;in&nbsp;Environmental Health Perspectives, <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/home-cooked-meals-linkedto-less-pfas/">people who eat more home-cooked meals have less exposure</a> to harmful per- and polyfluoroalkyl substances, a harmful substance commonly found in foods and&nbsp;food-contact materials, and have been linked to cancer.A group of researchers&nbsp;have developed <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/blood-test-may-eventually-speed-up-brain-cancer-diagnosis/">a&nbsp;blood test&nbsp;that may be able to more quickly diagnose patients with brain cancer</a>, thereby allowing them to seek treatment earlier and possibly increasing their chance for survival.<a href="https://www.docwirenews.com/hematology-oncology/circulating-tumor-dna-predicts-colorectal-cancer-relapse/">Circulating tumor DNA detected through&nbsp;liquid biopsy&nbsp;</a>is an independent predictor of patients with&nbsp;colorectal cancer&nbsp;who are likely to relapse after surgery, according to research presented at the ESMO Congress 2019.In case you missed it, more hem/onc headlines are featured below:<ul>
<li><a href="https://www.docwirenews.com/hematology-oncology/lymphoma-stage-at-diagnosis-may-predict-site-of-secondary-malignancy/">Lymphoma Stage at Diagnosis May Predict Site of Secondary Malignancy</a></li>
<li><a href="https://www.docwirenews.com/cardiology/exercise-reduces-heart-damage-related-to-chemotherapy/">Exercise Reduces Heart Damage Related to Chemotherapy</a></li>
<li><a href="https://www.docwirenews.com/hematology-oncology/cancer-patients-want-to-give-consent-before-their-data-is-used/">Cancer Patients Want to Give Consent Before Their Data is Used</a></li>
<li><a href="https://www.docwirenews.com/docwire-pick/3d-printing-breast-prosthetics-for-cancer-survivors-with-mastectomies/">3D Printing Breast Prosthetics for Cancer Survivors with Mastectomies</a></li>
<li><a href="https://www.docwirenews.com/hematology-oncology/multi-gene-testing-cost-effective-for-breast-cancer-patients/">Multi-Gene Testing is Cost-Effective for U.S. Breast Cancer Patients</a></li>
</ul>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Hem/Onc Roundup: Two Cancer Drugs Have Big Price Increases, Triplet Therapy for Pancreatic Cancer, and more

Oncology

Here are the top stories covered by DocWire Newsthis week in the Hematology &amp; Oncology section. This week, the Institute for Clinical and Economic Review (ICER) indicated ...

Hem/Onc Roundup: Two Cancer Drugs Have Big Price Increases, Triplet Therapy for Pancreatic Cancer,

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe